1. Home
  2. SWX vs RYTM Comparison

SWX vs RYTM Comparison

Compare SWX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Gas Holdings Inc. (DE)

SWX

Southwest Gas Holdings Inc. (DE)

HOLD

Current Price

$88.90

Market Cap

6.3B

Sector

Utilities

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$88.70

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWX
RYTM
Founded
1931
2008
Country
United States
United States
Employees
2453
414
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.2B
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
SWX
RYTM
Price
$88.90
$88.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
14
Target Price
$87.40
$131.14
AVG Volume (30 Days)
416.9K
713.2K
Earning Date
05-05-2026
05-05-2026
Dividend Yield
2.70%
N/A
EPS Growth
120.29
28.34
EPS
1.91
N/A
Revenue
$5,433,972,000.00
N/A
Revenue This Year
$18.48
$55.34
Revenue Next Year
$2.61
$86.06
P/E Ratio
$45.88
N/A
Revenue Growth
9.56
N/A
52 Week Low
$67.65
$58.71
52 Week High
$94.43
$122.20

Technical Indicators

Market Signals
Indicator
SWX
RYTM
Relative Strength Index (RSI) 44.98 47.71
Support Level $87.84 $87.19
Resistance Level $93.93 $92.17
Average True Range (ATR) 1.91 4.91
MACD -0.50 0.15
Stochastic Oscillator 20.27 41.94

Price Performance

Historical Comparison
SWX
RYTM

About SWX Southwest Gas Holdings Inc. (DE)

Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: